Intravitreal injection ranibizumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Choroidal Neovascularization
Conditions
Choroidal Neovascularization
Trial Timeline
Aug 1, 2007 → Apr 1, 2010
NCT ID
NCT00510965About Intravitreal injection ranibizumab
Intravitreal injection ranibizumab is a phase 2 stage product being developed by Novartis for Choroidal Neovascularization. The current trial status is completed. This product is registered under clinical trial identifier NCT00510965. Target conditions include Choroidal Neovascularization.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00504400 | Phase 2 | Completed |
| NCT00510965 | Phase 2 | Completed |
Competing Products
20 competing products in Choroidal Neovascularization
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 52 |
| Verteporfin Photodynamic Therapy + Ranibizumab | Novartis | Approved | 85 |
| ranibizumab | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Everolimus + Ranibizumab | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| ranibizumab 0.5mg | Novartis | Phase 2 | 52 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Phase 1/2 | 41 |
| Faricimab + Ranibizumab + Sham Procedure | Roche | Phase 2 | 52 |
| Faricimab + Ranibizumab | Roche | Phase 3 | 77 |
| Faricimab + Ranibizumab + Sham Procedure | Roche | Phase 2 | 52 |
| Intravitreal Pegaptanib | Pfizer | Pre-clinical | 22 |
| Intravitreal aflibercept injection 2.0mg | Regeneron Pharmaceuticals | Approved | 84 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Regeneron Pharmaceuticals | Pre-clinical | 22 |